107 related articles for article (PubMed ID: 1839532)
21. The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor.
Tulloch IF; Johnson AM
J Clin Psychiatry; 1992 Feb; 53 Suppl():7-12. PubMed ID: 1531829
[TBL] [Abstract][Full Text] [Related]
22. Concentration-response relationship in paroxetine treatment of diabetic neuropathy symptoms: a patient-blinded dose-escalation study.
Sindrup SH; Grodum E; Gram LF; Beck-Nielsen H
Ther Drug Monit; 1991 Sep; 13(5):408-14. PubMed ID: 1835549
[TBL] [Abstract][Full Text] [Related]
23. Fluoxetine disposition and elimination in cirrhosis.
Schenker S; Bergstrom RF; Wolen RL; Lemberger L
Clin Pharmacol Ther; 1988 Sep; 44(3):353-9. PubMed ID: 3262026
[TBL] [Abstract][Full Text] [Related]
24. Colchicine clearance is impaired in alcoholic cirrhosis.
Leighton JA; Bay MK; Maldonado AL; Schenker S; Speeg KV
Hepatology; 1991 Dec; 14(6):1013-5. PubMed ID: 1959847
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of cimetidine in patients with liver disease.
González-Martin G; Arancibia A; Fajuri M; Chesta J; Novoa X
Int J Clin Pharmacol Ther Toxicol; 1985 Jul; 23(7):355-8. PubMed ID: 4030163
[TBL] [Abstract][Full Text] [Related]
26. An overview of paroxetine.
Boyer WF; Feighner JP
J Clin Psychiatry; 1992 Feb; 53 Suppl():3-6. PubMed ID: 1531819
[TBL] [Abstract][Full Text] [Related]
27. Ability of charcoal to prevent absorption of paroxetine.
Greb WH; Buscher G; Dierdorf HD; von Schrader HW; Wolf D
Acta Psychiatr Scand Suppl; 1989; 350():156-7. PubMed ID: 2530777
[No Abstract] [Full Text] [Related]
28. Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis.
Haberer JP; Schoeffler P; Couderc E; Duvaldestin P
Br J Anaesth; 1982 Dec; 54(12):1267-70. PubMed ID: 7171414
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and protein binding of cefpiramide in patients with alcoholic cirrhosis.
Demotes-Mainard F; Vinçon G; Amouretti M; Dumas F; Necciari J; Kieffer G; Begaud B
Clin Pharmacol Ther; 1991 Mar; 49(3):263-9. PubMed ID: 2007321
[TBL] [Abstract][Full Text] [Related]
30. Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man.
Lund J; Thayssen P; Mengel H; Pedersen OL; Kristensen CB; Gram LF
Acta Pharmacol Toxicol (Copenh); 1982 Oct; 51(4):351-7. PubMed ID: 6217723
[TBL] [Abstract][Full Text] [Related]
31. Sufentanil pharmacokinetics in patients with cirrhosis.
Chauvin M; Ferrier C; Haberer JP; Spielvogel C; Lebrault C; Levron JC; Duvaldestin P
Anesth Analg; 1989 Jan; 68(1):1-4. PubMed ID: 2521279
[TBL] [Abstract][Full Text] [Related]
32. Famotidine pharmacokinetics following oral and intravenous administration in patients with liver disease: results of a preliminary study.
Morgan MY; Stambuk D
Postgrad Med J; 1986; 62 Suppl 2():29-37. PubMed ID: 2890149
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects.
Dimmitt DC; Cramer MB; Keung A; Arumugham T; Weir SJ
Cancer Chemother Pharmacol; 1999; 43(2):126-32. PubMed ID: 9923817
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of metoclopramide in patients with liver cirrhosis.
Magueur E; Hagege H; Attali P; Singlas E; Etienne JP; Taburet AM
Br J Clin Pharmacol; 1991 Feb; 31(2):185-7. PubMed ID: 2049236
[TBL] [Abstract][Full Text] [Related]
35. Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis.
Debruyne D; Gram LF; Grollier G; Camsonne R; Agron L; Dao MT; Lacotte J; Bigot MC; Moulin M
Int J Clin Pharmacol Res; 1989; 9(5):319-25. PubMed ID: 2625371
[TBL] [Abstract][Full Text] [Related]
36. Ranitidine disposition in severe hepatic cirrhosis.
Gonzalez-Martin G; Paulos C; Veloso B; Chesta J; Novoa X; Arancibia A
Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):139-42. PubMed ID: 3557740
[TBL] [Abstract][Full Text] [Related]
37. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and suggested oral dosing regimen of cisapride: a study in healthy cats.
LeGrange SN; Boothe DM; Herndon S; Willard MD
J Am Anim Hosp Assoc; 1997; 33(6):517-23. PubMed ID: 9358420
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests.
Brockmöller J; Thomsen T; Wittstock M; Coupez R; Lochs H; Roots I
Clin Pharmacol Ther; 2005 Jun; 77(6):529-41. PubMed ID: 15961984
[TBL] [Abstract][Full Text] [Related]
40. Altered pharmacokinetics of oral flecainide by cimetidine.
Tjandra-Maga TB; van Hecken A; van Melle P; Verbesselt R; de Schepper PJ
Br J Clin Pharmacol; 1986 Jul; 22(1):108-10. PubMed ID: 3741720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
